MedGenome, a global leader in genomics-driven diagnostics, has partnered with U.S.-based Twist Bioscience to launch the HOPE for Rare Diseases Program in India.
In a press statement on Thursday, the company informed that this initiative aims to provide affordable access to whole exome sequencing for economically disadvantaged patients, helping diagnose rare diseases more efficiently. The program, launched in August 2024, offers discounted genetic tests to patients from underprivileged backgrounds, aiming to ease the financial burden of diagnostics.
Twist Bioscience is contributing its Twist Exome 2.0 technology to the program, which enables researchers and clinicians to identify genetic variants responsible for rare diseases and inherited conditions. This technology supports healthcare providers in diagnosing and managing diseases more effectively. Despite being available for over a decade, such advanced sequencing methods have seen limited use in India due to high costs and a lack of awareness and insurance coverage.
MedGenome’s CEO highlighted that this partnership marks a significant step in democratising access to affordable genetic solutions in India, where over 70 million people—many of them children—suffer from rare genetic disorders. To shorten the often years-long diagnostic journey for these patients, the program offers hope for better disease management and treatment options
